The Medical Journal of Australia podcast: COVID-19 in children
MVEC's Associate Professor Nigel Crawford and Dr Laila Ibrahim, paediatrician and researcher at the Royal Children's Hospital feature on the latest edition of the Medical Journal of Australia podcast.
In this podcast, Nigel and Laila discuss COVID-19 in children, to accompany their co-authored research focused on examining the epidemiological and clinical characteristics of SARS‐CoV‐2‐positive children in Australia during 2020.
您可以在这里收听播客：
MJA Podcast: Episode 33: COVID-19 in children, with Dr Laila Ibrahim and Dr Nigel Crawford
八月 CVU 迷你活动现已开放报名
The next Clinical Vaccinology Update (CVU) miniseries event, 心脏问题：与 COVID-19 mRNA 疫苗接种相关的心肌炎和心包炎, will be held virtually on Monday 30th August 2021.
We are excited to welcome our panel who will take an in-depth look at an important vaccine safety signal associated with COVID-19 mRNA vaccines (Pfizer and Moderna), myocarditis and pericarditis. The session will also include a live Q&A panel with experts from the medical, consumer (Heart Foundation) and vaccine safety domains.
Further details can be found via our Events page and the link below:
ABC News: Why Delta COVID-19 variant could put younger people at risk of deadly cardiac complications
The COVID-19 Delta variant which is now subject of the current outbreaks in NSW, QLD and Victoria, has been linked to an increase in cases of cardiac complications in younger people. Though data is still emerging on how common the cardiac side effects are with the Delta variant, myocarditis has also been reported as a very rare side effect of mRNA COVID-19 vaccines (including Pfizer and Moderna) by the Australian Technical Advisory Group on Immunisation (ATAGI) .
According to a US study, while vaccine associated myocarditis and an associated condition, pericarditis (inflammation of the lining around the heart), could be serious, the likelihood of this occurring is low and most cases are reported to resolve quickly. Further to this, the study found that young people were around six times more likely to develop myocarditis from COVID than Pfizer, reiterating that the benefits of vaccination outweigh the risk of adverse effects from COVID-19, including for myocarditis.
To read the article in full please click on the link below:
ABC: Why Delta COVID-19 variant could put younger people at risk of deadly cardiac complications
TGA grants provisional approval for the Moderna COVID-19 vaccine (Spikevax) Elasomeran
We have updated our Moderna COVID-19 vaccination page to reflect the announcement by the Australian Technical Advisory Group on Immunisation (ATAGI) regarding the use of Moderna's COVID-19 vaccine.
On August 9 2021, The Therapeutic Goods Administration (TGA) granted provisional approval to Moderna Australia Pty Ltd for its COVID-19 vaccine—Spikevax (elasomeran).
To find out more information, please refer to our dedicated MVEC Moderna COVID-19 vaccination page in the link below.
MVEC Moderna COVID-19 vaccination page
Inside Aesthetics podcast featuring A/Prof Nigel Crawford
Associate Professor Nigel Crawford is interviewed by Dr Jake Sloane (cosmetic doctor and international injectables trainer) and David Segal (a multi-clinic owner and aesthetic entrepreneur) on their Inside Aesthetics podcast. In this episode, Nigel discusses the current vaccination landscape including vaccine safety, risk-benefit analysis, and COVID-19 vaccination in pregnancy.
您可以在这里收听播客：
Inside Aesthetics Podcast featuring Associate Professor Nigel Crawford
Updated MVEC reference page: Myocarditis and pericarditis following COVID-19 mRNA vaccines
We have updated our myocarditis and pericarditis following COVID-19 vaccines page to reflect the guidance by the Australian Technical Advisory Group on Immunisation (ATAGI) and the Cardiac Society of Australia and New Zealand (CSANZ).
ATAGI and CSANZ emphasise that the overwhelming benefits of vaccination in protecting against COVID-19 greatly outweigh the rare risk of these conditions, and Comirnaty (Pfizer mRNA vaccine) continues to be recommended for all people ≥ 16 years of age who do not have any contraindications to the vaccine, in those aged 12-15 with specific medical conditions that increase their risk of severe illness from COVID-19, and in Aboriginal and Torres Strait Islanders aged 12-15.
要了解更多信息，请参阅下面链接中的专门针对 COVID-19 疫苗接种后的 MVEC 心肌炎和心包炎页面。
MVEC myocarditis and pericarditis following COVID-19 vaccines page
ATAGI statement on the use of a different COVID-19 vaccine as the second dose
The Australian Technical Advisory Group on Immunisation (ATAGI) has released clinical guidance on the use of a different COVID-19 vaccine as the second dose.
The advice recommends to use the same COVID-19 vaccine for the 2 doses of the primary vaccination course, unless there are specific medical reasons not to do so, or the same vaccine brand is not available in Australia.
The ATAGI advice explains:
• The medical contraindications and serious vaccine-attributable adverse events after
dose 1 of a COVID-19 vaccine that warrant using an alternative vaccine brand for dose 2
• The medical conditions that mean that Comirnaty is recommended over COVID-19
Vaccine AstraZeneca
• The recommendations for completing the primary vaccination course for people who
have received dose 1 with a vaccine that is not available in Australia.
To read the statement in full, please click the link below:
ATAGI statement: ATAGI clinical advice on use of a different COVID-19 vaccine as the second dose in special circumstances
For further information on COVID-19 mixed vaccine schedules refer to MVEC: COVID-19 mixed vaccine schedules.
Updated MVEC reference page: COVID-19 vaccination in children
We have updated our COVID-19 vaccination in children page to reflect the statement by the Australian Technical Advisory Group on Immunisation (ATAGI) regarding vaccination of adolescents aged 12-15 years.
The following groups of children among those aged 12–15 years are to be prioritised for vaccination using the Comirnaty (Pfizer) vaccine:
- Children with specified medical conditions that increase their risk of severe COVID-19 (including severe asthma, diabetes, obesity, cardiac and circulatory congenital anomalies, neuro developmental disorders, epilepsy, immuno-compromised and trisomy 21)
- Aboriginal and Torres Strait Islander children aged 12–15 years
- All children aged 12–15 years in remote communities, as part of broader community outreach vaccination programs that provide vaccines for all ages (≥12 years).
To find out more information, please refer to our dedicated MVEC COVID-19 vaccination in children page in the link below.
MVEC COVID-19 vaccination in children page
COSSI 网络研讨会视频现已推出 - 强制性 COVID-19 疫苗接种网络研讨会
最近 COSSI 网络研讨会的录音 强制性 COVID-19 疫苗接种 现在可用。该网络研讨会于 7 月 26 日举行，讨论了强制接种 COVID-19 疫苗的政策、行为、伦理和流行病学方面的问题。
如需查看录音，请点击以下链接：
COSSI 网络研讨会视频现已推出 - 强制性 COVID-19 疫苗接种网络研讨会
Change in timing for Pfizer second dose (in Victoria)
In order for more Victorians to receive their first dose of a COVID-19 vaccine, it is now recommended dose 2 of Pfizer COVID-19 vaccine (Comirnaty™) is administered 6 weeks after dose 1.
Individuals who currently have their second dose of Comirnaty™ booked do not need to reschedule their appointments.
This change only applies in Victoria.
For further information refer to the link below:
Department of Health: Change in timing for Pfizer second dose